Novo Nordisk Pharma (Thailand) Ltd. has signed a Memorandum of Understanding (MOU) with the Faculty of Medicine Siriraj Hospital, Mahidol University. The aim is to promote collaboration in the study and research of medications for diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. This collaboration will also provide opportunities for patients to participate in clinical research and offers researchers more options in clinical studies. Additionally, this partnership also aims to facilitate training, joint research projects, and the exchange of innovative information and knowledge.
The MOU signing ceremony was a momentous occasion, graced by the esteemed presence of Prof. Apichat Asavamongkolkul, Dean of the Faculty of Medicine Siriraj Hospital, Mahidol University. Prof. Asavamongkolkul, alongside Mr. Enrico Cañal Bruland, Vice President and General Manager of Novo Nordisk Pharma (Thailand) Ltd., officially signed the MOU, marking a significant milestone in healthcare collaboration. The ceremony was further enriched by the attendance of Assoc. Prof. Winai Ratanasuwan, Director of the Siriraj Institute of Clinical Research (SiCRES), other distinguished faculty members from Siriraj Hospital, and executives from Novo Nordisk.
A highlight of the ceremony was the presentation of a commemorative plaque from Novo Nordisk to the Faculty of Medicine Siriraj Hospital, symbolizing the enduring commitment and shared vision of both institutions. This event not only celebrated the formalization of the MOU but also set the stage for future innovations and advancements in diabetes and obesity research.
The event featured an academic seminar on "State-of-the-Art Transformations in Diabetes and Obesity Management," providing insights into innovative approaches and treatments for diabetes and obesity. Speakers included Assist. Prof. Dr. Kusuma Chaiyasoot from the Division of Clinical Nutrition, Prof. Apiradee Sriwijitkamol, and Assoc. Prof. Jeerunda Santiprabhob from the Division of Pediatrics Endocrinology and Metabolism. The session was moderated by Prof. Nattachet Plengvidhya from the Division of Endocrinology and Metabolism. The seminar concluded with a session on “Transforming Clinical Research Through Innovative Medicines” by Novo Nordisk, drawing significant interest from faculty members, medical students, researchers, and attendees. The event took place at the Sirindhorn Conference Room, G Floor, Chalermprakiat Building, Faculty of Medicine Siriraj Hospital.
About Siriraj Institute of Clinical Research (SICRES)
SICRES is an academic clinical research institute that operates under the Faculty of Medicine Siriraj Hospital, Mahidol University. Our mission is to conduct and support clinical research trials to transform patient care, improve human health, and better the community. We conduct cost-effective clinical research at international standards and provide full-service clinical trial design and management. Our vision is to become the most trusted academic clinical research organization in Southeast Asia. www.sicres.org/
About Faculty of Medicine Siriraj Hospital, Mahidol University
The Faculty of Medicine Siriraj Hospital is the oldest medical institute in Thailand. It was founded in 1888 by His Majesty King Chulalongkorn. The institute seeks to produce high-quality medical graduates, research and publications, as well as medical services with international standards. The hospital’s mission is to improve the health and quality of life of Thais and the broader international community. https://www2.si.mahidol.ac.th/en/
About Novo Nordisk Pharma (Thailand) Ltd.
Novo Nordisk Pharma (Thailand) Ltd. has been a steadfast presence in Thailand for over 40 years. The parent company, Novo Nordisk, headquartered in Denmark, is a leading global healthcare organization founded in 1923, and celebrated its centennial year in 2023. Our primary focus is on the research and development of innovative medicines aimed at improving the quality of life for patients suffering from diabetes and other chronic conditions such as obesity, rare blood disorders, and endocrine disorders. Our mission is to drive change for better health today and for future generations through the development of innovative treatments and integrated prevention strategies. www.novonordisk.co.th